Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion.
Bowers. C Y CY; Granda-Ayala. R R
Key Findings
- A low dose of GHRPâ2 (0.1âŻÂ”g/kg) boosts the GH response to a standard dose of GHRH, indicating synergy.
- Higher single doses of GHRPâ2 (1â10âŻÂ”g/kg) produce a strong, doseâdependent increase in GH, roughly twice as high at 10âŻÂ”g/kg.
- Continuous subâcutaneous infusion of 1âŻÂ”g/kg/h GHRPâ2 for 30 days sustains elevated pulsatile GH secretion and raises serum IGFâ1.
Practical Outcomes
- For biohackers looking to raise GH and IGFâ1, a protocol using GHRPâ2 aloneâstarting around 1âŻÂ”g/kg and possibly up to 10âŻÂ”g/kgâcan be effective. Combining a tiny dose of GHRPâ2 with GHRH may enhance the GH spike while using less GHRH. A lowâdose continuous infusion (â1âŻÂ”g/kg/h) appears to keep GH and IGFâ1 elevated over weeks, offering a practical way to maintain higher anabolic hormone levels.
Summary
In older men and women who have low growth hormone (GH) and IGFâ1, giving the peptide GHRPâ2 can jumpâstart GH release. Even a small dose of GHRPâ2 makes the body respond better to a GHâreleasing hormone, and higher doses give a much bigger GH spike. Using a steady lowâdose GHRPâ2 infusion for a month keeps GH pulses and IGFâ1 levels higher than before.
Abstract
To better appreciate the interactions of GHRP-2 and GHRH 1-44NH2 on the release of GH in normal adult men and women with decreased GH secretion and low serum IGF-1 levels, a series of acute and chronic studies have been performed (n = 5 men, 5 women). The acute iv bolus GH responses of these subjects to the two peptides alone and together suggest that the decreased GH secretion may be primarily due to a deficiency of the natural endogenous GHRP, ghrelin, rather than a decreased secretion of endogenous GHRH or excess secretion of SRIF. To determine whether the low GH response to GHRH was due to a limited capacity of pituitary to release GH, higher dosages of GHRP-2 alone were administered. At a dose of 1 microg/kg GHRP-2 the GH response was essentially the same as that elicited by 1 microg/kg GHRH + 0.1 microg/kg GHRP-2 while the GH response to 10 microg/kg GHRP-2 sc was about twice as high in both men and women. Although these subjects have a limited pituitary capacity to release GH, which is also an indication of decreased GH secretion in the presence of low serum IGF-1 levels, this alone would not explain the low GH response to GHRH. Furthermore, the finding that a low dose of 0.1 microg/kg GHRP-2 augments the GH response to 1 microg/kg GHRH is strongly against an excess secretion of SRIF. Twenty-four hour profiles of GH secretion during placebo, GHRP-2, and various doses of GHRH alone and together with GHRP-2 were studied. In addition, 1 microg/kg/h GHRP-2 was infused continuously sc to these subjects for 30 d. The normal pulsatile secretion of GH as well as the serum IGF-1 level was increased after 24 h and remained elevated for 30 d. With a deficiency of endogenous GHRH, the GH response of GHRP-2 would be little to none, while in subjects with a deficiency of the natural GHRP, the GH response to GHRH would be more attenuated. Thus, in chronic deficiency the GH response would be expected to depend on the degree of the capacity of the pituitary to release GH as well as the type(s) of hormonal deficiency.
Study Information
pubmed
2001
10.1385/endo:14:1:079